OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Amanam on the Evolution of Myelofibrosis Management

October 11th 2024

Idoroenyi Amanam, MD, discusses potential treatment advancements in myelofibrosis and highlights the use of stem cell transplant in this disease.

Dr Hernandez-Ilizaliturri on Selecting Between CAR T-Cell Therapies for FL

October 11th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.

Dr Sridhar on the Use of Zelenectide Pevedotin in Locally Advanced or Metastatic Urothelial Cancer

October 11th 2024

Srikala Sridhar, MD, MSc, FRCPC, discusses the unique application of zelenectide pevedotin, which targets nectin-4 in locally advanced or metastatic urothelial cancer.

Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in Mesothelioma

October 11th 2024

Andrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.

Dr Lentzsch on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Suzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr Lorusso on Relacorilant Plus Nab-Paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer

October 11th 2024

Domenica Lorusso, MD, PhD, discusses findings from a trial evaluating relacorilant plus nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.

Dr Voss on the Evaluation of Nivolumab/Ipilimumab in Intermediate/Poor-Risk RCC

October 11th 2024

Martin H. Voss, MD, discusses the evaluation of nivolumab plus ipilimumab in IMDC-classified intermediate/poor-risk renal cell carcinoma.

Dr Sands on Updated Efficacy Findings With Tarlatamab in Previously Treated SCLC

October 10th 2024

Jacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.

Dr Voss on Cabozantinib Plus Nivolumab and Updated NCCN Guidelines in RCC

October 10th 2024

Martin H. Voss, MD, discusses a trial of cabozantinib plus nivolumab in renal cell carcinoma and how it relates to updated NCCN treatment guidelines.

Dr Mehta on Risks of CAR T-cell Therapy in Heavily Pretreated Lymphoma Patients

October 10th 2024

Amitkumar Mehta, MD, discusses CAR T-cell therapy-associated risks in patients with lymphoma who have undergone multiple lines of prior chemotherapy.

Dr Adige on the Importance of Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses the importance of recognizing Breast Cancer Awareness Month and highlights key insights into understanding the disease.

Dr Jain on Treatment Considerations in the Frontline Management of CLL

October 9th 2024

Nitin Jain, MD, discusses current treatment options and considerations for the frontline management of CLL.

Dr Ng on Treatment Considerations for Younger Patients With CRC

October 9th 2024

Kimmie Ng, MD, MPH, discusses treatment considerations for younger patients with colorectal cancer.

Dr Garassino on the Potential Use of a TROP2 Biomarker to Predict Outcomes With Dato-DXd in NSCLC

October 8th 2024

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

Dr Jabbour on the Role of Bosutinb as a Therapeutic Option for TKI-Pretreated CML

October 8th 2024

Elias Jabbour, MD, discusses the role of bosutinib as a standard treatment for patients with CML that is resistant or intolerant to prior TKI therapy.

Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in Myeloma

October 8th 2024

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

Dr Wander on Managing HR+ Advanced Breast Cancer in the Clinic

October 8th 2024

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

Dr Rutkowski on Avelumab Plus Axitinib in Unresectable/Metastatic GIST

October 8th 2024

Piotr Rutkowski, MD, discusses an investigation of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression.

Dr Martín-Broto on the Efficacy of Sunitinib Plus Nivolumab in Clear Cell Sarcoma

October 8th 2024

Javier Martín Broto MD, PhD, discusses the efficacy of treatment with sunitinib plus nivolumab in clear cell sarcoma, according to the IMMUNOSARC II trial.

Dr Girard on the Safety of Nivolumab/Relatlimab/Chemotherapy in Untreated NSCLC

October 8th 2024

Nicolas Girard, MD, discusses the safety of nivolumab plus relatlimab and chemotherapy for untreated stage IV or recurrent non–small cell lung cancer.